AI Article Synopsis
- Hyaluronic acid (HA) is a promising tool in anticancer drug delivery due to its biocompatibility, biodegradability, and the ability to target tumor cells with CD44 receptors.
- Recent advancements are exploring various HA-based platforms for drug carriers, including conjugates and nanoparticle technologies, to enhance cancer treatment.
- The review covers chemical strategies and details about HA drug delivery systems, highlighting preclinical and clinical findings to support their effectiveness.
Article Abstract
Hyaluronic acid (HA) is widely used in anticancer drug delivery, since it is biocompatible, biodegradable, non-toxic, and non-immunogenic; moreover, HA receptors are overexpressed on many tumor cells. Exploiting this ligand-receptor interaction, the use of HA is now a rapidly-growing platform for targeting CD44-overexpressing cells, to improve anticancer therapies. The rationale underlying approaches, chemical strategies, and recent advances in the use of HA to design drug carriers for delivering anticancer agents, are reviewed. Comprehensive descriptions are given of HA-based drug conjugates, particulate carriers (micelles, liposomes, nanoparticles, microparticles), inorganic nanostructures, and hydrogels, with particular emphasis on reports of preclinical/clinical results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.addr.2015.11.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!